Phase 2 Start

UTHR: Phase 2 Start: Phase 2 Study to Assess the Safety and Efficacy of Bomedemstat (IMG-7289) in Combination With Momelo

Name: Phase 2 Start: Phase 2 Study to Assess the Safety and Efficacy of Bomedemstat (IMG-7289) in Combination With Momelo
Start: 2026-11-01
End: 2026-11-01

November 1, 2026 · momelotinib. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date: November 1, 2026
Company: UNITED THERAPEUTICS Corp (UTHR)
Drug: momelotinib

BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 2 Start~month

Phase 2 Start: Phase 2 Study to Assess the Safety and Efficacy of Bomedemstat (IMG-7289) in Combination With Momelo

November 1, 2026

UTHR overview →

Company: UNITED THERAPEUTICS Corp (UTHR)
Drug: momelotinib
Indication: Myelofibrosis

Other upcoming events for UTHR

Phase 3 ReadoutPhase 3 Topline: Opiate-sparing Post-operative Pain Control in Septorhinoplasty: A Prospective Randomized, Double Bli

Sep 1, 2026

Phase 3 ReadoutPhase 3 Topline: A Phase 3 Open-label Extension (OLE) Study to Evaluate the Long-term Safety and Efficacy of Ralinepa

Dec 1, 2026